EUVIMEDEUVIMED entdecken
Übersichtsarbeit

T‐Cell Redirecting Strategies in Large B‐Cell Lymphoma and Follicular Lymphoma

Gloria Iacoboni iD

Hematological Oncology · 2025

DOI: 10.1002/hon.70068 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Hematological Oncology, 2025. Verfasst von Gloria Iacoboni. Beteiligte Einrichtung: Department of Hematology, Vall d'Hebron University Hospital, Barcelona, Spain. Hauptthemen laut MEDLINE: Lymphoma, Follicular, Immunotherapy, Adoptive, Lymphoma, Large B-Cell, Diffuse, T-Lymphocytes. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 134 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The advent of chimeric antigen receptor (CAR) T‐cell therapy has revolutionized the treatment landscape of relapsed/refractory large B‐cell lymphoma (LBCL). After achieving regulatory approval in third line (3L+), randomized trials confirmed superiority over standard‐of‐care salvage chemoimmunotherapy (CIT) and autologous stem‐cell transplantation in patients experiencing progressive disease within 12 months of first‐line treatment. On the other hand, bispecific antibodies (BsAbs) are approved in the 3L+, while trials are exploring their potential in an earlier setting, usually in combination with CIT. In follicular lymphoma (FL), both T‐cell redirecting strategies are approved in 3L+. The higher response rate with CAR T cells in FL comes at the cost of an increased toxicity risk and logistical barriers, in comparison with off‐the‐shelf BsAbs. This review focuses on the role of CAR T cells and BsAbs in LBCL and FL, paying special attention to available results and sequencing approaches.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, FollicularImmunotherapy, AdoptiveLymphoma, Large B-Cell, DiffuseT-LymphocytesAntibodies, BispecificHumansReceptors, Chimeric Antigen

Stichwörter der Autor:innen

CAR T cellsbispecific antibodiesdiffuse large B‐cell lymphomafollicular lymphoma

Substanzen

Receptors, Chimeric AntigenAntibodies, Bispecific

Autor:innen und Institutionen

  • Department of Hematology, Vall d'Hebron University Hospital, Barcelona, Spain.
  • Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.

ORCID-Profile: Gloria Iacoboni

Zitieren

APA

Iacoboni, G. (2025). T‐Cell Redirecting Strategies in Large B‐Cell Lymphoma and Follicular Lymphoma. Hematological Oncology. https://doi.org/10.1002/hon.70068

Vancouver

Iacoboni G. T‐Cell Redirecting Strategies in Large B‐Cell Lymphoma and Follicular Lymphoma. Hematological Oncology. 2025. doi:10.1002/hon.70068

BibTeX
@article{Iacoboni2025,
  author = {Iacoboni, Gloria},
  title = {T‐Cell Redirecting Strategies in Large B‐Cell Lymphoma and Follicular Lymphoma},
  journal = {Hematological Oncology},
  year = {2025},
  doi = {10.1002/hon.70068}
}
Kostenlos starten →